Search
Iproclozide
go.drugbank.com/drugs/DB09247ApprovedWithdrawnfatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).
AT-301
go.drugbank.com/drugs/DB16507InvestigationalAT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine
Berberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnAn alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. … Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis.
Atipamezole
go.drugbank.com/drugs/DB11481InvestigationalVet approvedAtipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. … It has also been undergone research as a potential anti-Parkinsonian drug for humans.
Aprindine
go.drugbank.com/drugs/DB01429ExperimentalAprindine is a cardiac depressant used in arrhythmias.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IbIratumumab
go.drugbank.com/drugs/DB05550InvestigationalMolecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.
Nilvadipine
go.drugbank.com/drugs/DB06712ApprovedNilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalIt was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
Gemopatrilat
go.drugbank.com/drugs/DB20954ExperimentalGemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.
Categories: Agents Acting on the Renin-Angiotensin System